Alamar Biosciences, Inc.
NASDAQ:ALMRBiotechnology
+$1.11 today
- Market cap
- $2.12B
- Beta
- 0.00
- P/E (TTM)
- -47.5
- EPS (TTM)
- -$0.45
Volume 0.53M
Average 0.38M
ALMR Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Alamar Biosciences, Inc.NASDAQ: ALMR
Cost of Revenue · Q2 FY2026 · quarter ended Jun 2026
Cost of revenue of $11.71M in Q2 FY2026
Q2 FY2026 cost of revenue was $11.71M.
Context
- Cost of revenue amounted to 43.8% of revenue in FY2025.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 32.51M USD
- Year-over-year change
- —
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 32.51M | — |
Cost of Revenue vs competitors
How ALMR compares with its peers on the latest reported figures
- ALMR's FY2025 cost of revenue of $32.51M is the 6th highest of the 9 companies compared; the peer median is $72.64M.
- Cost of revenue amounts to 43.8% of revenue for ALMR, versus a peer median of 51.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $420.61M | -0.2% | +4.3% | 34.2% | |
| LTM Sep 2026 | $218.63M | +17.8% | +12.1% | 47.6% | |
| LTM Sep 2026 | $173.93M | -13.0% | +18.2% | 28.1% | |
| LTM Mar 2026 | $100.69M | -21.2% | +11.3% | 62.9% | |
| LTM Mar 2026 | $44.6M | -34.2% | -11.1% | 51.7% | |
ALMRAlamar Biosciences, Inc. | FY2025 | $32.51M | — | — | 43.8% |
| LTM Mar 2026 | $7.78M | -27.0% | -0.2% | 51.7% | |
| LTM Mar 2026 | $6.32M | -43.5% | +23.7% | — | |
| LTM Mar 2026 | $1.11M | -31.7% | — | 60.0% | |
| Peer median (excluding ALMR) | $72.64M | -24.1% | +11.3% | 51.7% | |
Competitors are the stored peer set for ALMR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2025 Dec 2025 |
|---|---|
| Revenue | 74.21M |
| Cost of Revenue | 32.51M |
| Gross Profit | 41.71M |
| Gross Margin | 56.2% |
| Research & Development | 37.47M |
| Selling, General & Admin | 35.57M |
| Operating Expenses | 73.04M |
| Depreciation & Amortization | 3.86M |
| EBITDA | (24.89M) |
| EBITDA Margin | -33.5% |
| Operating Income | (31.33M) |
| Operating Margin | -42.2% |
| Interest Income | 2.16M |
| Interest Expense | 401K |
| Other Income / Expenses | 2.18M |
| Income Before Tax | (29.15M) |
| Pre-Tax Margin | -39.3% |
| Income Tax Expense | 665K |
| Net Income | (29.82M) |
| Net Margin | -40.2% |
| EPS (Basic) | (0.45) |
| EPS (Diluted) | (0.45) |
| Weighted Avg Shares | 66.52M |
| Weighted Avg Shares (Diluted) | 66.52M |
Alamar Biosciences, Inc.
NASDAQ:ALMR
Intrinsic Alpha fair value
Locked
Current Price
$30.51
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.